Assembly Bio Reports Third Quarter 2026 Results

The biotech posted a $20.3 million net loss as it advances its hepatitis delta program and holds $314.3 million in cash.

Updated on Nov. 12, 2026 in Biotech

Photograph of an empty laboratory bench with clean glass flasks and pipettes, with a window behind showing foggy hills.
Assembly Biosciences reported a $20.3 million third-quarter net loss and $314.3 million in cash as it advances its hepatitis delta program. AI Illustration. Upload story photo >

Assembly Biosciences reported third quarter 2026 financial results and disclosed it exercised its 40% U.S. profit-share option for the HSV helicase-primase inhibitor program. The South San Francisco company posted a net loss attributable to common stockholders of $20.3 million, or $0.93 per share, for the period ended September 30, 2026.

Why it matters

The results reflect a shift in how the company shares development costs and revenue on its herpes program, with Gilead now leading further development. Cash reserves plus a $75 million collaboration extension fee are projected to fund operations into 2029, giving the company runway for its hepatitis delta work.

Assembly Bio reported $3.0 million in Gilead collaborative research revenue, down from $10.8 million a year earlier, after an $11.3 million reduction in the transaction price of the HPI license. The company's $314.3 million in cash and marketable securities is projected to fund operations into 2029, though the filing does not detail the timing of future milestone payments.

The players

Assembly Biosciences, Inc.

A South San Francisco biotechnology company developing antiviral therapies for hepatitis B, hepatitis delta and herpes simplex virus infections, and a collaboration partner with Gilead Sciences.

Gilead Sciences

A major California-based biopharmaceutical company with a large antiviral portfolio that now leads further development of the HSV helicase-primase inhibitor program shared with Assembly Bio.

The details

The company initiated a Phase 2 clinical study of ABI-6250 in chronic hepatitis delta virus infection and received a $75 million collaboration extension fee from Gilead in November 2026. Under the profit-share arrangement, Assembly Bio is responsible for 40% of U.S. development costs for the helicase-primase inhibitor program, which Gilead now leads.

Timeline

  1. September 30, 2025: Prior-year comparison period for quarterly results.

  2. June 30, 2026: Comparison date for prior-quarter cash position.

  3. September 30, 2026: End of the third quarter 2026 reporting period.

  4. November 2026: Assembly Bio received the $75 million Gilead collaboration extension fee.

  5. First quarter 2027: Planned start of the ABI-6250 Phase 2 study in cholestatic liver diseases.

Pipeline Context

The results follow the structure of Assembly Bio's earlier Gilead partnership, in which the company shares costs and revenue on the herpes program rather than carrying it alone. The company's shift toward hepatitis delta, through its ABI-6250 study, reflects a broader pattern of small antiviral developers concentrating on chronic viral indications with partner-led commercialization.

For patients with chronic hepatitis delta or recurrent herpes, the results signal that development work is continuing on new antiviral candidates, though no approved treatment is expected from these studies in the near term. The company's funding runway into 2029 suggests the programs are not facing an immediate cash-driven slowdown.

The takeaway

Assembly Bio's shift to sharing development costs on its herpes program shows how small biotechs can extend their cash runway while larger partners take the lead on late-stage work. Readers tracking antiviral development should watch the first quarter 2027 start of the hepatitis delta study.

What happens next

Assembly Biosciences expects to begin the Phase 2 ABI-6250 study in cholestatic liver diseases in the first quarter of 2027, and Gilead anticipates starting a Phase 2 study of GS-1179 for recurrent genital herpes by the end of 2026.

Further reading

For more on the sector, explore Biotech coverage of drug development partnerships and clinical pipelines.

Source note: This article includes information reported by The Manila times.